Targovax ASA: Invitation to fourth quarter and ful

Oslo, Norway, 6 February 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its fourth quarter and full year 2016 results on Thursday, 16 February 2017. A presentation by Targovax's management to investors, analysts and the press will take place in Oslo at 10:00 CET.

The results report and the presentation will be available at www.targovax.com in the Investors section from 07:00 CET.

Presentation The presentation will take place at 10:00 CET at:

Hotel Continental Stortingsgaten 24/26 0117 Oslo

The presentation will also be webcast live and can be accessed through www.targovax.com.

Conference call At 14:00 CET (08:00 EST) The company will host a telephone conference which will include a presentation of the results, following a Q&A session. CEO Øystein Soug will present the company.  Call in details can be found below.

Call-in numbers: Norway Toll-Free Number: 800 19 747 Norway Toll Number: +472350 0559 UK Toll-Free Number: 08082370030 UK Toll Number: +442031394830 US Toll-Free Number: 1866 928 7517 US Toll Number: +1 718 873 9077

Access code: 54717166#

Please make sure to dial in at least 5-10 minutes ahead to complete your registration.

See attached list for more dial-in numbers. http://events.arkadin.com/ev/docs/NE_FEL_Even...s_List.pdf

For further information, please contact: Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com

Media and IR enquires: Jan Petter Stiff - Crux Advisers (Norway) Phone: +47 995 13 891 Email: stiff@crux.no

Julia Phillips/Simon Conway - FTI Consulting (International) Phone: +44 20 3727 1000 Email: Targovax@fticonsulting.com

About Targovax

Arming the patient's immune system to fight cancer

Targovax is a clinical stage company focused on developing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

The Company's development pipeline has arisen from two novel proprietary platforms:

The first platform, ONCOS, uses oncolytic viruses, an emerging class of biological therapy. ONCOS exclusively uses an adenovirus that has been engineered to be a tumor-targeted immune activator. The platform has the potential to generate therapies with superior efficacy and safety compared to the first approved oncolytic virus therapy, Imlygic, recently launched by Amgen. We expect proof of concept data related to immune activation in tumor tissue in 2017 from the clinical trial of ONCOS-102 in combination wih CPI in patients with refractory malignant melanoma.

The second platform, TG-Peptides, solely targets tumors that express mutated forms of the RAS protein. Mutations to this protein are common in many cancers and are known to drive aggressive disease progression and treatment resistance. There is a high unmet medical need for therapies that are effective against tumors that express these mutations. The TG platform's therapeutic potential stems from its ability to enable a patient's immune system to identify and then destroy tumors bearing any RAS mutations.  

The development pipeline has three novel therapeutic candidates in clinical development covering six indications and has already demonstrated promising safety and tolerability data and early signs of clinical response.

Both platforms are protected by an extensive portfolio of IP and know-how and have the potential to yield multiple product candidates in a cost effective manner. Our portfolio of future opportunities comprises a number of early stage development candidates in addition to the three outlined above. In July 2016 the Company listed its shares on Oslo Axess, securing funding for further development of the Company's ongoing and planned trials.

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.